Tag: ixekizumab

Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits

Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits

| June 1, 2019

The editors of JCAD are pleased to present this biannual column as a means to recognize select medical students, PhD candidates, and other young investigators in the field of dermatology for their efforts in scientific writing. We hope that the publication of their work encourages these and other emerging authors to continue their efforts in […]

Continue Reading

Recommendations for Initiating Systemic Therapy in Patients with Psoriasis

Recommendations for Initiating Systemic Therapy in Patients with Psoriasis

| April 1, 2019

J Clin Aesthet Dermatol. 2019;12(4):13–26 by George Martin, MD; Melodie Young, MSN, ANP-C; and Lakshi Aldredge, MSN, ANP-BC Dr. Martin is with Dr. George Martin Dermatology Associates in Kihei, Hawaii. Ms. Young is with Modern Research Associates in Dallas, Texas. Ms. Aldredge is with the VA Portland Health Care System in Portland, Oregon. FUNDING: The authors […]

Continue Reading

Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis

Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis

| May 1, 2018

by Saakshi Khattri, MD; Orin Goldblum, MD; Kathleen Solotkin, MSN; Yasmin Amir, MD; Michelle S. Min, MD, MSci; Terri Ridenour, BSN, MBA; Fan Emily Yang, PhD; and Mark Lebwohl, MD, FAAD Dr. Khattri, Dr. Amir, Dr. Min, and Dr. Lebwohl are with the Department of Dermatology at the Icahn School of Medicine at Mount Sinai […]

Continue Reading